ANRis Inc. was established to deliver less burdensome medicine to patients who are fighting cancer and other genetic diseases by developing the technology of nucleic acid medicines, focused on siRNA (small interfering RNA). Prof. Kumiko Ui-Tei at The University of Tokyo discovered the innovative sequence design approach, SNPD-siRNA (Single Nucleotide Polymorphism-Distinguishable siRNA), which overcomes siRNA medicine’s off-target effects that suppresses the normal mRNA as well as the target mRNA. This ground-breaking method enables the specific suppression of mRNA exclusively containing single nucleotide mutations, elevating precision, and efficacy in therapeutic interventions.

ANRis Inc. is a hybrid drug discovery venture that provides medicines for diseases targeting driver gene mutations. Nowadays, expectations for the development of nucleic acid therapeutics are getting higher and higher around the world, we brought the best scientists in Japan together to implement SNPD-siRNA technology and take on the challenge of providing medical treatments that are personalized to each patient suffering from cancer and genetic diseases.